Jean I Liu
CIK 1241357 · Chief Legal Officer · last filed 2026-10-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SGEN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BOTHELL, WA 98021
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CNTB | Director | 20,763 | $0.75 | $15.5K | $0 | 3 | 2026-10-01 |
| ERAS | Director | — | $14.04 | — | $0 | 8 | 2026-06-29 |
| Seagen Inc. (SGEN) Delisted | Chief Legal Officer | 0 | $228.74 | $0 | -$22.94M | 52 | 2023-12-15 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | VP & General Counsel | 16,187 | — | — | $0 | 5 | 2014-02-10 |
| DURECT CORP (DRRX) Delisted | Chief Legal Officer | 18,463 | $1.91 | $35.3K | $0 | 11 | 2011-07-13 |
Recent Filings · Page 7 of 9
85 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-08-08 | Seagen Inc. (SGEN) Delisted | Sell (S) | −3,716 | -$278.7K | EDGAR |
| 2018-09-04 | Seagen Inc. (SGEN) Delisted | Grant (A) | +17,608 | $0 | EDGAR |
| 2018-08-29 | Seagen Inc. (SGEN) Delisted | Sell (S) | −4,123 | -$306.1K | EDGAR |
| 2018-03-22 | Seagen Inc. (SGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-06 | Seagen Inc. (SGEN) Delisted | Disp (D) | −7,536 | -$448.8K | EDGAR |
| 2017-08-18 | Seagen Inc. (SGEN) Delisted | Grant (A) | +17,000 | $0 | EDGAR |
| 2016-08-30 | Seagen Inc. (SGEN) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
| 2015-08-25 | Seagen Inc. (SGEN) Delisted | Grant (A) | +14,000 | $0 | EDGAR |
| 2014-12-03 | Seagen Inc. (SGEN) Delisted | Grant (A) | +22,400 | $0 | EDGAR |
| 2014-02-10 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.